Hotaling Investment Management’s Charles River Laboratories CRL Stock Holding History

Hotaling Investment Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-929	Closed	-$350K	–	133
2021 Q4	$350K	Buy	929 +9	+1%	+$3.5K	0.12%	100
2021 Q3	$380K	Buy	920 +50	+6%	+$20.8K	0.16%	90
2021 Q2	$322K	Hold	870	–	–	0.13%	101
2021 Q1	$252K	Sell	870 -52	-6%	-$14.5K	0.11%	98
2020 Q4	$230K	Sell	922 -14	-1%	-$3.33K	0.11%	98
2020 Q3	$212K	Buy	+936	New	+$194K	0.11%	102
2020 Q2	–	Sell	-1,670	Closed	-$211K	–	106
2020 Q1	$211K	Sell	1,670 -107	-6%	-$16K	0.16%	93
2019 Q4	$271K	Buy	1,777 +15	+0.9%	+$2.08K	0.16%	93
2019 Q3	$233K	Buy	1,762 +15	+0.9%	+$2.01K	0.15%	96
2019 Q2	$248K	Buy	1,747 +20	+1%	+$2.71K	0.16%	101
2019 Q1	$251K	Buy	+1,727	New	+$227K	0.17%	103

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Hotaling Investment Management's CRL Position: Q1 2022 in Review

Hotaling Investment Management sold out of Charles River Laboratories (CRL) in Q1 2022, closing a stake of 929 shares — an estimated $350K sold.

Hotaling Investment Management first reported a position in CRL in Q1 2019 and held it in 11 quarters. The position peaked at $380K in Q3 2021. 644 funds tracked by Wall St. Rank hold CRL as of Q1 2022.

Hotaling Investment Management reported no remaining Charles River Laboratories position as of Q1 2022 after selling out during the quarter.
Hotaling Investment Management sold 929 Charles River Laboratories shares in Q1 2022, an estimated $350K.
Hotaling Investment Management first reported a position in Charles River Laboratories in Q1 2019 and held it in 11 quarters.
Hotaling Investment Management's Charles River Laboratories position peaked at $380K in Q3 2021.
644 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2022.

Based on Hotaling Investment Management's 13F filing for Q1 2022, filed 22 Apr 2022.